CTOs on the Move

Tango Therapeutics

www.tangotx.com

 
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today`s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tangotx.com
  • 100 Binney Street Suite 700
    Cambridge, MA USA 02142
  • Phone: 857.320.4900

Executives

Name Title Contact Details

Funding

Tango Therapeutics raised $60M on 04/09/2020
Tango Therapeutics raised $50M on 08/17/2020

Similar Companies

Perseus

Perseus is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OnePointOne

Located in Silicon Valley, OnePointOne is revolutionizing vertical farming by building the most technologically advanced cultivation platform on the planet through innovations in automation, AI and plant science.

Seventh Wave

Seventh Wave is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kallyope

At Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology. Founded and headquartered in New York City, we are developing an industry-leading platform to harness the gut-brain axis. Our cross-disciplinary biotechnology team will integrate cutting-edge technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics and consumer products to improve human health and nutrition.

Aastrom

We are committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.